Blog

Healthcare innovation

UAE’s health sector witnesses two new international…

UAE’s health sector witnesses two new international…

The UAE’s health sector is seeing increased interest from global pharma and healthcare majors, with Emirates Health Services (EHS) and Moorfields Eye Hospital Abu Dhabi being the latest to announce new deals.

Emirates Health Services has entered into a memorandum of understanding (MoU) with Novo Nordisk Pharma Gulf to collaborate on areas of common interest, most notably in healthcare innovation.

The MoU, signed by Dr. Yousif Mohammed Al Serkal, Director-General of EHS, and Mads Bo Larsen, vice president and general manager of Novo Nordisk Pharma Gulf, envisages the pharma company providing 12 months of free treatment with its oral Semaglutide drug for 50 patients with type 2 diabetes.

UAE

It will also support physicians in the emirate with scientific communication for management of the disease.

The two entities will also collaborate on educational programmes and panel discussions for healthcare providers at hospitals and healthcare centres under the EHS umbrella that offer diabetes treatments.

In the second deal, Imperial College London Diabetes Centre (ICLDC), part of the Mubadala Health network, has announced a partnership with Moorfields Eye Hospital Abu Dhabi, to provide ophthalmology services for the former’s patients in Abu Dhabi.

The tie-up with Moorfields Eye Hospital Abu Dhabi, also a Mubadala Health Partner, followed a partnership with Moorfields London, a leader in ophthalmology services in the UK.

Patients will now have access to ophthalmic services delivered by Moorfields physicians at the ICLDC Khaleej Al Arabi branch, in Abu Dhabi.

This is in line with both entities’ aim to offer patients access to world-class healthcare services closer to home.

Eye disease is one of the most common conditions dealt with by people who suffer from diabetes, as diabetic retinopathy affects blood vessels in the retina, and may lead to vision loss and blindness if it goes untreated.

Through this partnership, ICLDC patients will have access to a vast range of ophthalmology treatments and surgical interventions, including those for retinal or corneal conditions, strabismus, laser and refractive procedures, glaucoma, cataract and genetic eye diseases.

The services have already begun operations within the ICLDC Khaleej Al Arabi branch, available by appointment to patients within the centre’s usual working hours.

For all the latest business news from the UAE and Gulf countries, follow us on Twitter and Linkedin, like us on Facebook and subscribe to our YouTube page, which is updated daily.

Source